Clinigen Group PLC (CLIN) Insider Shaun Edward Chilton Sells 97,246 Shares
Clinigen Group PLC (LON:CLIN) insider Shaun Edward Chilton sold 97,246 shares of the stock in a transaction that occurred on Tuesday, October 18th. The stock was sold at an average price of GBX 750 ($9.14), for a total value of £729,345 ($888,903.11).
Clinigen Group PLC (LON:CLIN) opened at 772.50 on Wednesday. Clinigen Group PLC has a 52 week low of GBX 492.75 and a 52 week high of GBX 793.50. The company’s market capitalization is GBX 885.28 million. The firm’s 50-day moving average price is GBX 695.99 and its 200-day moving average price is GBX 612.87.
The company also recently announced a dividend, which will be paid on Friday, November 25th. Investors of record on Thursday, November 3rd will be given a dividend of GBX 2.70 ($0.03) per share. The ex-dividend date of this dividend is Thursday, November 3rd. This is an increase from Clinigen Group PLC’s previous dividend of $1.30. This represents a yield of 0.38%.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/19/clinigen-group-plc-clin-insider-shaun-edward-chilton-sells-97246-shares.html
CLIN has been the subject of a number of recent analyst reports. N+1 Singer reissued a “buy” rating and issued a GBX 800 ($9.75) price objective on shares of Clinigen Group PLC in a report on Wednesday, September 28th. Stifel Nicolaus reaffirmed a “buy” rating and set a GBX 800 ($9.75) price target on shares of Clinigen Group PLC in a research note on Wednesday, July 20th. Peel Hunt reaffirmed a “buy” rating and set a GBX 1,000 ($12.19) price target on shares of Clinigen Group PLC in a research note on Tuesday. Finally, Numis Securities Ltd reaffirmed a “buy” rating and set a GBX 916 ($11.16) price target on shares of Clinigen Group PLC in a research note on Wednesday, July 20th. Five investment analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus price target of GBX 856.60 ($10.44).
Clinigen Group PLC Company Profile
Clinigen Group plc is a United Kingdom-based global pharmaceutical and services company. The Company consists of four businesses that provide medicines to patients with unmet needs, through clinical trials, licensed and unlicensed supply. It operates through four segments: Clinigen Clinical Trial Services (CTS), Idis Managed Access (MA), Idis Global Access (GA) and Clinigen Specialty Pharmaceuticals (SP).
Receive News & Ratings for Clinigen Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.